AKRX

Akorn, Inc. News Headlines

$41.71
*  
0.42
1.02%
Get AKRX Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading AKRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
5 Best Biotech Stocks to Buy Now
10/21/2014 10:33:02 AM - InvestorPlace Media


First Week of AKRX November 22nd Options Trading
9/24/2014 12:24:17 PM - BNK Invest


Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog
9/23/2014 4:55:00 PM - Zacks.com


Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
9/18/2014 4:30:00 PM - Zacks.com


Stocks with Upgraded Broker Ratings - Screen of the Week
9/16/2014 3:57:00 AM - Zacks.com


AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
9/12/2014 5:05:00 PM - Zacks.com


Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
9/10/2014 4:45:00 PM - Zacks.com


Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
9/8/2014 5:20:00 PM - Zacks.com


Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
9/5/2014 5:05:00 PM - Zacks.com


Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
9/4/2014 4:30:00 PM - Zacks.com


Akorn (AKRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
9/3/2014 8:54:00 AM - Zacks.com


UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
8/28/2014 4:40:00 PM - Zacks.com


Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
8/21/2014 4:30:00 PM - Zacks.com


Should You Get Rid of Corium International (CORI) Now? - Tale of the Tape
8/20/2014 8:55:00 AM - Zacks.com


First Week of AKRX October 18th Options Trading
8/19/2014 1:53:10 PM - BNK Invest


Mallinckrodt Acquires Questcor, to Join S&P 500 As Well - Analyst Blog
8/18/2014 4:30:00 PM - Zacks.com


Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
8/18/2014 1:30:00 PM - Zacks.com


Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
8/14/2014 1:29:00 PM - Zacks.com


Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
8/14/2014 9:25:00 AM - Zacks.com


Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View - Analyst Blog
8/13/2014 1:23:00 PM - Zacks.com


Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
8/11/2014 9:46:00 AM - Zacks.com


Zacks Rank #1 Additions for Monday - Tale of the Tape
8/11/2014 9:30:00 AM - Zacks.com


Why Akorn (AKRX) Might Be a Diamond in the Rough - Tale of the Tape
8/11/2014 8:34:00 AM - Zacks.com


Akorn Q2 14 Earnings Conference Call At 10:00 AM ET
8/5/2014 9:01:00 AM - RTT News


Akorn Q2 Profit Declines, Adj. Earnings Top Estimates; Lifts FY Outlook
8/5/2014 8:09:00 AM - RTT News